Nepstar Fails To Acquire Wulin Drugstore
This article was originally published in PharmAsia News
Executive Summary
With no firm agreement reached between the two parties, Nepstar Chain Drugstore has dropped its bid to acquire Hangzhou Wulin Drugstore (PharmAsia News, Sep.15, 08). Wulin Drugstore seeks funding from cash-rich Nepstar, which listed overseas, but industry observers note that the derailed deal may be due to the latter's financial problems, partly caused by the weakened U.S. dollar. The current financial turmoil may have dampened Nepstar's confidence in the drug retail industry, thus its change of mind. However, the firm said that it has enough money from its IPO for expansion and the stock market has little impact on its finances. (Click here for more - Chinese Language)
You may also be interested in...
Nepstar Suspends Acquisition Of Wulin Drugstore
Nepstar Chain Drugstore has suspended its acquisition of Hangzhou Wulin Drugstore due to a lack of consensus on the terms of agreement. Sources reveal that the deal is worth about RMB 40 million and price was the key issue that stalls the process. After buying 68 drugstores under Ningbo Xinshiji Pharmaceutical's Drug Chain with RMB 30 million (PharmAsia News March 3, 2008) and Huirentang's 18 chain drugstores in Dongguan for RMB 2.3 million (PharmAsia News March 17, 2008) early this year, Nepstar was all set to acquire Wulin Drugstores. The firm aims to open 1,050 new shops by acquisition within 2008. However, the plan may derail due to high top-level management turnover that reflects the pressure to perform amidst its rapid expansion. (Click here for more - Chinese Language)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.